PRGO Stock Analysis: Perrigo | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 1.896m USD | 12M Return: -34% | IE00BGH1M568 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 32.9M
EPS Trend: 14.9%
Qual. Beats: 1
Rev. Trend: -97.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Perrigo Company plc (NYSE: PRGO) is a Dublin-based provider of over-the-counter (OTC) consumer self-care products, operating through Consumer Self-Care Americas and Consumer Self-Care International segments. Founded in 1887 and headquartered in Ireland, the company sells branded and private-label health and wellness items across upper respiratory, nutrition (including infant formula and electrolyte beverages), digestive health, pain and sleep, oral care, skin care, womens health, and vitamins/minerals/supplements categories, under brands such as Mederma, Plackers, REACH, Nasonex, Prevacid24HR, Opill, Solpadeine, and ellaOne.
Distribution spans retail drug, supermarket, and mass merchandise chains, e-commerce, wholesalers, pharmacies, and para-pharmacies, with the company also offering contract manufacturing services. Perrigo is widely recognized as one of the worlds largest manufacturers of private-label/store-brand OTC products, a business model in which retailers sell the companys formulations under their own labels, complementing its portfolio of owned brands.
- Opill OTC contraceptive adoption drives segment growth
- Store brand pricing pressure impacts Consumer Self-Care margins
- European segment revenue declines on weak demand
| Net Income: -1.73b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.24 > 1.0 |
| NWC/Revenue: 33.70% < 20% (prev 34.42%; Δ -0.72% < -1%) |
| CFO/TA 0.03 > 3% & CFO 251.8m > Net Income -1.73b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (139.6m) vs 12m ago 1.01% < -2% |
| Gross Margin: 33.26% > 18% (prev 35.73%; Δ -2.46% > 0.5%) |
| Asset Turnover: 46.83% > 50% (prev 42.86%; Δ 3.97% > 0%) |
| Interest Coverage Ratio: -9.11 > 6 (EBIT TTM -1.49b / Interest Expense TTM 163.1m) |
| A: 0.18 (Total Current Assets 2.45b - Total Current Liabilities 1.05b) / Total Assets 7.61b |
| B: -0.53 (Retained Earnings -4.00b / Total Assets 7.61b) |
| C: -0.17 (EBIT TTM -1.49b / Avg Total Assets 8.85b) |
| D: 0.49 (Book Value of Equity 2.52b / Total Liabilities 5.09b) |
| Altman-Z'' = -1.12 = CCC |
| DSRI: 1.12 (Receivables 761.2m/706.6m, Revenue 4.14b/4.33b) |
| GMI: 1.07 (GM 35.73% / 33.26%) |
| AQI: 0.90 (AQ_t 0.57 / AQ_t-1 0.63) |
| SGI: 0.96 (Revenue 4.14b / 4.33b) |
| TATA: -0.26 (NI -1.73b - CFO 251.8m) / TA 7.61b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of August 23, 2026, the stock is trading at USD 14.25 with a total of 2,581,744 shares traded. Over the past week, the price has changed by +9.28%, over one month by +36.10%, over three months by +28.82% and over the past year by -33.98%.
Current recommended Stop Loss: 13.20 (which is 7.4% or 1.7 ATR below the current price).
Perrigo has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold PRGO.
- StrongBuy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 16.5 | 15.8% |
P/E Forward = 6.5232
P/S = 0.4573
P/B = 0.77
P/EG = 1.1418
Revenue TTM = 4.14b USD
EBIT TTM = -1.49b USD
EBITDA TTM = -1.35b USD
Long Term Debt = 3.28b USD (from longTermDebt, last quarter)
Short Term Debt = 11.4m USD (from shortTermDebt, last quarter)
Debt = 3.47b USD (from shortLongTermDebtTotal, last quarter) + Leases 173.0m
Net Debt = 3.07b USD (calculated: Debt 3.47b - CCE 399.7m)
Enterprise Value = 4.96b USD (1.90b + Debt 3.47b - CCE 399.7m)
Interest Coverage Ratio = -9.11 (Ebit TTM -1.49b / Interest Expense TTM 163.1m)
EV/FCF = 28.36x (Enterprise Value 4.96b / FCF TTM 175.0m)
FCF Yield = 3.53% (FCF TTM 175.0m / Enterprise Value 4.96b)
FCF Margin = 4.22% (FCF TTM 175.0m / Revenue TTM 4.14b)
Net Margin = -41.85% (Net Income TTM -1.73b / Revenue TTM 4.14b)
Gross Margin = 33.26% ((Revenue TTM 4.14b - Cost of Revenue TTM 2.77b) / Revenue TTM)
Gross Margin QoQ = 30.69% (prev 33.58%)
Tobins Q-Ratio = 0.65 (Enterprise Value 4.96b / Total Assets 7.61b)
Interest Expense / Debt = 4.70% (Interest Expense 163.1m / Debt 3.47b)
Taxrate = 16.03% (16.9m / 105.4m)
NOPAT = -1.25b (EBIT -1.49b * (1 - 16.03%)) [loss with tax shield]
Current Ratio = 2.32 (Total Current Assets 2.45b / Total Current Liabilities 1.05b)
Debt / Equity = 1.38 (Debt 3.47b / totalStockholderEquity, last quarter 2.52b)
Debt / EBITDA = -2.28 (negative EBITDA) (Net Debt 3.07b / EBITDA -1.35b)
Debt / FCF = 17.53 (Net Debt 3.07b / FCF TTM 175.0m)
Total Stockholder Equity = 3.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.60% (Net Income -1.73b / Total Assets 7.61b)
RoE = -55.97% (Net Income TTM -1.73b / Total Stockholder Equity 3.10b)
RoCE = -23.29% (EBIT -1.49b / Capital Employed (Equity 3.10b + L.T.Debt 3.28b))
RoIC = -19.63% (negative operating profit) (NOPAT -1.25b / Invested Capital 6.36b)
WACC = 5.89% (E(1.90b)/V(5.36b) * Re(9.44%) + D(3.47b)/V(5.36b) * Rd(4.70%) * (1-Tc(0.16)))
Discount Rate = 9.44% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.24 | Cagr: 0.64%
[DCF] Terminal Value 73.10% ; FCFF base≈207.7m ; Y1≈182.1m ; Y5≈147.1m
[DCF] Fair Price = N/A (negative equity: EV 2.36b - Net Debt 3.07b = -706.2m; debt exceeds intrinsic value)
EPS Correlation: 14.91 | EPS CAGR: 1.33% | SUE: 0.84 | # QB: 1
Revenue Correlation: -97.60 | Revenue CAGR: -4.04% | SUE: 0.49 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.53 | Chg30d=-6.27% | Revisions=-50% | Analysts=4
EPS current Year (2026-12-31): EPS=2.19 | Chg30d=+3.81% | Revisions=+57% | GrowthEPS=-20.4% | GrowthRev=-4.5%
EPS next Year (2027-12-31): EPS=2.40 | Chg30d=+1.54% | Revisions=+57% | GrowthEPS=+9.6% | GrowthRev=+0.7%
[Analyst] Revisions Ratio: +36% (up=8, down=3)